These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18980226)

  • 1. HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses.
    D'Souza S; Yang W; Marchetti D; Muir C; Farach-Carson MC; Carson DD
    J Cell Biochem; 2008 Dec; 105(5):1183-93. PubMed ID: 18980226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells.
    Reiland J; Kempf D; Roy M; Denkins Y; Marchetti D
    Neoplasia; 2006 Jul; 8(7):596-606. PubMed ID: 16867222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor.
    Ferreras C; Rushton G; Cole CL; Babur M; Telfer BA; van Kuppevelt TH; Gardiner JM; Williams KJ; Jayson GC; Avizienyte E
    J Biol Chem; 2012 Oct; 287(43):36132-46. PubMed ID: 22927437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of heparin/heparan sulfate interacting protein/ribosomal protein l29 during the estrous cycle and early pregnancy in the mouse.
    Julian J; Das SK; Dey SK; Baraniak D; Ta VT; Carson DD
    Biol Reprod; 2001 Apr; 64(4):1165-75. PubMed ID: 11259264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis.
    Cole CL; Hansen SU; Baráth M; Rushton G; Gardiner JM; Avizienyte E; Jayson GC
    PLoS One; 2010 Jul; 5(7):e11644. PubMed ID: 20657775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perlecan domain I gradients establish stable biomimetic heparin binding growth factor gradients for cell migration in hydrogels.
    Hubka KM; Carson DD; Harrington DA; Farach-Carson MC
    Acta Biomater; 2019 Oct; 97():385-398. PubMed ID: 31351252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIP/RPL29 down-regulation accompanies terminal chondrocyte differentiation.
    Miller SA; Brown AJ; Farach-Carson MC; Kirn-Safran CB
    Differentiation; 2003 Aug; 71(6):322-36. PubMed ID: 12919102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?
    Hoß SG; Grundmann M; Benkel T; Gockel L; Schwarz S; Kostenis E; Schlesinger M; Ilan N; Vlodavsky I; Bendas G
    Thromb Haemost; 2018 Oct; 118(10):1803-1814. PubMed ID: 30235481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 4-deoxy analogue of N-acetyl-D-glucosamine inhibits heparan sulphate expression and growth factor binding in vitro.
    van Wijk XM; Oosterhof A; van den Broek SA; Griffioen AW; ten Dam GB; Rutjes FP; van Delft FL; van Kuppevelt TH
    Exp Cell Res; 2010 Sep; 316(15):2504-12. PubMed ID: 20433828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of microvascular signaling by heparan sulfate matrix: studies in syndecan-4 transgenic mice.
    Li J; Partovian C; Li J; Hampton TG; Metais C; Tkachenko E; Sellke FW; Simons M
    Microvasc Res; 2002 Jul; 64(1):38-46. PubMed ID: 12074629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound.
    Miao HQ; Ornitz DM; Aingorn E; Ben-Sasson SA; Vlodavsky I
    J Clin Invest; 1997 Apr; 99(7):1565-75. PubMed ID: 9120000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Site-Selectively Mono-6-O-Sulfated Heparan Sulfate Dodecasaccharide Shows Anti-Angiogenic Properties In Vitro and Sensitizes Tumors to Cisplatin In Vivo.
    Avizienyte E; Cole CL; Rushton G; Miller GJ; Bugatti A; Presta M; Gardiner JM; Jayson GC
    PLoS One; 2016; 11(8):e0159739. PubMed ID: 27490176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of HIP/RPL29 expression induces differentiation in colon cancer cells.
    Liu JJ; Huang BH; Zhang J; Carson DD; Hooi SC
    J Cell Physiol; 2006 May; 207(2):287-92. PubMed ID: 16475173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-O Heparan Sulfate Sulfation by Hs2st Is Required for Erk/Mapk Signalling Activation at the Mid-Gestational Mouse Telencephalic Midline.
    Chan WK; Howe K; Clegg JM; Guimond SE; Price DJ; Turnbull JE; Pratt T
    PLoS One; 2015; 10(6):e0130147. PubMed ID: 26075383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
    Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
    Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous ribosomal protein L29 (RPL29): a newly identified regulator of angiogenesis in mice.
    Jones DT; Lechertier T; Reynolds LE; Mitter R; Robinson SD; Kirn-Safran CB; Hodivala-Dilke KM
    Dis Model Mech; 2013 Jan; 6(1):115-24. PubMed ID: 23118343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport of fibroblast growth factor 2 in the pericellular matrix is controlled by the spatial distribution of its binding sites in heparan sulfate.
    Duchesne L; Octeau V; Bearon RN; Beckett A; Prior IA; Lounis B; Fernig DG
    PLoS Biol; 2012 Jul; 10(7):e1001361. PubMed ID: 22815649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
    Sasaki T; Larsson H; Kreuger J; Salmivirta M; Claesson-Welsh L; Lindahl U; Hohenester E; Timpl R
    EMBO J; 1999 Nov; 18(22):6240-8. PubMed ID: 10562536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate.
    Chadderton NS; Stringer SE
    Int J Biochem Cell Biol; 2003 Jul; 35(7):1052-5. PubMed ID: 12672474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.